Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bifidobacterium breve BBr60
- Development stage
- Unknown
- Lead developer
- Wecare Probiotics
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifidobacterium breve BBr60 is a strain-specific **live biotherapeutic/probiotic microbial therapy** based on *Bifidobacterium breve*, studied as an oral intervention for obesity-related metabolic dysfunction and for general physiological and psychological health in adults. In the provided public sources, BBr60 was administered orally at **1 × 10^10 CFU/day** and evaluated in randomized, double-blind, placebo-controlled human trials. In overweight or obese adults, the strain was reported to improve weight-related measures and fasting blood glucose and to modulate gut microbiota, serum and fecal metabolites, and metabolic pathways linked to lipid handling, amino acid metabolism, oxidative phosphorylation, and cholesterol metabolism. Its mechanism is not defined by a single human molecular target; rather, it appears to act through **microbiome modulation**, altered microbial metabolite production, and downstream effects on host metabolic and gut barrier physiology. The cited studies identify **Wecare Probiotics** as the product manufacturer/supplier, and the available evidence supports development primarily in **obesity/overweight-associated metabolic health**, with an additional investigator-initiated healthy-volunteer study examining gastrointestinal, metabolic, and mood-related endpoints.
- Other names
- Bifidobacterium breve BBr60
Beyond the preview
Go deeper on Bifidobacterium breve BBr60.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bifidobacterium breve BBr60.